Oxygen Biotherapeutics, Inc. (OXBO) and U.S. Navy Expand Collaboration With a Cooperative Research & Development Agreement to Study Oxycyte® for Treatment of Hemorrhagic Shock
8/2/2012 10:39:27 AM
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a development stage biomedical company focused on developing oxygen-carrying intravenous and topical products, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Unit of San Antonio (NAMRU-SA) to assess the safety and efficacy of Oxycyte® as well as hemoglobin-based oxygen carriers (HBOC) as potential resuscitation treatments for hemorrhagic shock. This latest CRADA is in addition to separate, ongoing research programs in which the U.S. Navy is exploring the therapeutic potential of Oxycyte in the areas of decompression sickness and traumatic brain injury.
comments powered by